Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began churning out incredulous terror in December 2019. Within several months from its first detection in Wuhan, SARS-CoV-2 spread to the rest of the world through droplet infection, making it a pandemic situation and a healthcare emergency across the globe. The available treatment of COVID-19 was only symptomatic as the disease was new and no approved drug or vaccine was available. Another challenge with COVID-19 was the continuous mutation of the SARS-CoV-2 virus. Some repurposed drugs, such as hydroxychloroquine, chloroquine, and remdesivir, received emergency use authorization in various countries, but their clinical use is compromised with either severe and fatal adverse effects or nonavailability of sufficient clinical data. Molnupiravir was the first molecule approved for the treatment of COVID-19, followed by Paxlovid™, monoclonal antibodies (MAbs), and others. New molecules have variable therapeutic efficacy against different variants or strains of SARS-CoV-2, which require further investigations. The aim of this review is to provide in-depth information on new molecules and repurposed drugs with emphasis on their general description, mechanism of action (MOA), correlates of protection, dose and dosage form, route of administration, clinical trials, regulatory approval, and marketing authorizations.
Background: Diabetes mellitus (DM), a metabolic disorder mainly characterized by hyperglycemia, causes the damage of various organs including the eyes, liver, kidney and heart. It is evident that diet plays a key role in the management of DM. Objective: The present study aimed to evaluate the effect of Zn and Mg supplemented diets as an adjuvant therapy with glibenclamide on streptozotocin (STZ)-induced diabetic rats. Methods: The rats who showed a blood glucose level of 200 mg/dL or higher, after 48 h of STZ injection, were considered as diabetic. The rats were divided into eight groups in which the normal control group comprised of non-diabetic rats whereas the rest of the groups had diabetic rats in which glibenclamide (5 mg/kg) with an ordinary diet was given to positive control group whereas test groups were treated with glibenclamide with specific diets. Blood glucose, body weight and lipid profile, as well as the liver and kidney functions, were evaluated using standard kits after a certain interval upto 21 days. Results: Glibenclamide at different doses with or without Zn and Mg significantly decreased blood glucose, cholesterol, triglyceride, urea, creatinine, total bilirubin and LDL whereas increased the HDL level. The study revealed that glibenclamide together with Zn and Mg-rich diet showed the most significant (p<0.0001) results. Conclusion: The treatment of diabetes mellitus with glibenclamide can produce better results if used with Zn and Mg-rich diet which can be a potential adjuvant therapy for type-2 diabetes and its associated complications.